Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doravirine + islatravir
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doravirine + islatravir is an investigational, once-daily, oral, two-drug fixed-dose combination regimen for the treatment of HIV-1 infection in adults. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 reverse transcriptase by binding to a distinct site and blocking DNA polymerization. Islatravir is a first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTTI), which acts as an immediate and delayed chain terminator during viral DNA synthesis by inhibiting the translocation step of reverse transcription. The combination aims to provide potent antiviral activity with a high barrier to resistance and favorable safety profile. Developed by Merck, this regimen has demonstrated non-inferiority to standard three-drug antiretroviral therapies in phase 3 trials for virologically suppressed adults with HIV-1[3][4][6][7].
- Brand names
- IDVYNSO
- Other names
- DOR/ISL
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on doravirine + islatravir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doravirine + islatravir.